BIO Patrik Frei, Switzerland/Singapore

Dr. Patrik Frei is founder and CEO of Venture Valuation AG, Switzerland. He started the company over 14 years ago when he noticed a need for independent valuation services in high growth industries during a collaboration with Novartis Venture Fund, which became his first client. Since then he has been involved in over 300 valuations for investors as well as biotech, Pharma and medtech companies. Patrik graduated from the Business University of St. Gallen and completed his Ph.D thesis (”Assessment and valuation of high growth companies”) at the Swiss Federal Institute of Technology, EPFL Lausanne. Patrik was a board member and one of the original founders of Ineo, a holding company of the Swiss dental implant VC-backed firm Thommen Medical. He is also the Chairman of Ophthalmopharma, a Swiss based biotech ophthalmology company, where he successfully out-licensed a portfolio of 4 products. Furthermore, Patrik is member of the board of Kleinkraftwerk Birseck AG (KKBN:Berne) a publicly quoted cleantech company. Patrik’s articles have been published in a number of scientific journals including “Nature Biotechnology”, “Chimia” and other business publications (“Starting a Business in the Life Sciences: From Idea to Market” and “Building Biotechnology: Starting, Managing, and Understanding Biotechnology Companies”). He has also lectured at Seoul National University, South Korea, EPFL Lausanne, University of St. Gallen and gives regular workshops on valuation.

中文 | English
  • UPCOMING WORKSHOPS
  • PAST WORKSHOPS

    • Lingmed workshop - how to out license innovation to access to foreign investment
    by Patrik from Switzerland

    LINGMED LIMITED SHANGHAI together with Venture Valuation is pleased to invite you to
    a full-day workshop on Biotech-Pharma Product and Company Valuation for fundraising

    Valuation is a key factor for any biotech and pharma company raising money or trying to license a product. Learn how to calculate and determine the right assumption for any therapeutic product (pre-clinical, clinical or on the market) to structure a suitable licensing deal and understand how to assess a biotech company for financing rounds and M&A
    About the workshop
    1-Day Training Course by Dr. Patrik Frei
    • Patrik has over 25 years' experience in biotechnology and life sciences
    • He is Europe's top valuation expert
    • Patrik is author of a number of Nature and other publications on valuation
    • He is the founder and CEO of Venture Valuation providing independent valuations in Asia, Pacific, Europe and North America
    • Patrik has written his own book "Assessment and valuation of high growth companies"
    • Patriks company runs and owns Biotechgate, a global database for the Life Sciences industry
    • Patrik and his team have worked for a number of the top 10 pharma companies
    • Patrik has taught valuation workshops to pharma companies in-house as well as at Universities, research organisations in Australia, Asia, Europe and the US
    Participants of the course will Why you should attend Whether you raise money, try to out or in-licence products as a business development or you would like just a basic understanding of how valuation works, this is the ideal introduction course for you. As a total beginner or even if you already have some valuation experience, the specific application of valuation in the biotechnology and life sciences field of this course will give you a great introduction or refresh of this complex topic
    The content Fundraising and Valuation in Life Sciences are probably some of the most difficult tasks. What deal terms can you ask for or what should be the equity share to a new investor? Who are the right investors. These are critical question for most life sciences companies. However, valuation is more than just numbers – its about the assumptions and about understanding the business, so it comes down to the potential of a product or company and the associated risk
    The expert Patrik has worked for over 18 years in the field of biotechnology and product valuations, having Novartis Venture Fund as his first client. With over 500 valuations around the world, multiple publications and top-tier clients, Patrik is the leading expert
    Learning methodology The concept of this course is to provide an introduction to the financial and business aspect of valuation and basics of fund raising. With a combination of a practical based presentation followed by two case studies (one for a company valuation and one for a product valuation and licensing deal), the participants will be able to learn hand-on, how to do a valuation. The provided Excel model for the product valuation (rNPV) can be used and will be provided as a take-home tool as well. The case studies will be done in groups to also allow networking during the course and provide interactive learning
    Who should attend? Anybody active in the life sciences industry and involved in fundraising, licensing, technology transfer and business development. Often participants are biotech or pharma executives, investors, technology transfer officers, consultants, business development or pharma executives. Both people with either a pure finance or a scientific background can benefit from this introduction course
    Agenda
    08:30
    Registration & Welcome coffee
    08:45
    Welcome
    09:00
    Introduction to Valuation: what –why –when
    - The main drivers of valuation: measuring risk vs. return
    09:30
    Fundraising for Biotech companies
    • What investor match your company
    • How to find the right investor
    • Dos and don'ts when raising money
    10:00
    How to assess a company prior to valuation
    • Why is it important to assess a company before doing a valuation
    • The three key assessment areas: management – technology – market
    • The 20 factors required to assess a company
    10:45
    Coffee break
    11:00
    Company Valuation
    • An overview of approaches for valuing life science
    • Focus on the most used company valuation methods
    • Discount cash flows
    • Venture capital method
    • Market / deal comparable
    Group work on a case study：
    The audience will be broken up in groups. After reading the case, each group has the opportunity to calculate the value of a Digital Health company. The groups will then present and discuss their results in a plenary discussion
    13:00
    Lunch
    14:00
    Product valuation & deal structuring
    • Difference between company and product valuation
    • What information do you need? - How to gather the information?
    • Overview of product valuation methods
    • In-depth explanation of the most frequently used technique in Pharma & Biotech:the Risk-adjusted Net Present Value(rNPV)
    • How to calculate the value of a company from several product valuations
    • Given an rNPV, how to decide on the best deal structure (upfront payment, milestone payments, royalties and etc?)
    • How to use the product valuation to determine a suitable deal structure?
    Group work on a case study
    The audience will be broken up in groups.After reading the case, each group has the opportunity to calculate the value of a pharmaceutical product in development. The groups will then present and discuss their results in a plenary discussion

    Coffee will be served during the case study workshop
    16:45
    Final Discussion & Wrap-up
    17:00
    Closing
    For any further enquiries, please contact info@lingmed.cn or +86 21 5386 3003, stating your name and company.
    REGISTER
    ©Copyright 2013 - Lingmed Limited